Maze Therapeutics, Inc. share price logo

Maze Therapeutics, Inc.

NASDAQ: MAZE

Small Cap

$24.23

-0.44

(-1.78%)

as on

Maze Therapeutics, Inc. Stock Performance

as on September 16, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $24.15
    $24.79
    downward going graph

    0.33%

    Downside

    2.31%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $22.04
    $53.65
    downward going graph

    9.04%

    Downside

    121.42%

    Upside

    downward going graph

Maze Therapeutics, Inc. share price movements today

Previous Close
$24.67
Open
$24.32
Volume
488.5K
Market Cap
$1.4B
Day's Low - High
$24.15 - $24.79
52 Week Low - High
$22.04 - $53.65

Maze Therapeutics, Inc. Historical Returns

1 Month Return
-9.23 %
3 Month Return
+ 1.65 %
1 Year Return
+ 6.11 %
3 Year Return
0 %
5 Year Return
0 %

Maze Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Maze Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.4B

EPS (TTM)

-2.74

Dividend Yield

0.00%

PE Ratio (TTM)

-8.98

Industry PE ratio

-6.33

PEG Ratio

0.17101983894702527

Return On Equity TTM

-34.94%

Maze Therapeutics, Inc. Stock Valuation

Track how Maze Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Maze Therapeutics, Inc. in the last 4 years

  • Overview

  • Trends

Lowest (-13.58x)

December 31, 2025

Today (-13.58x)

December 31, 2025

Industry (-6.33x)

December 31, 2025

Highest (205.01x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -13.58x

Maze Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Maze Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Maze Therapeutics, Inc. image
Maze Therapeutics, Inc.
StrongBuy$1.4BNA-8.9895.28%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$130.6B175.08%29.7686.04%NA
Moderna image
Moderna
BUY$57.5B-66.24%-18.04-12.57%NA
Regeneron image
Regeneron
BUY$80.5B21.74%18.9584.86%47.339999999999996%

Stock Returns calculator for Maze Therapeutics, Inc. Stock including INR - Dollar returns

The Maze Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Maze Therapeutics, Inc. investment value today

Current value as on today

₹1,13,769

Returns

₹13,769

(+13.77%)

Returns from Maze Therapeutics, Inc. Stock

₹4,215 (+4.22%)

Dollar Impact

₹9,554 (+9.55%)

Analyst Recommendation on Maze Therapeutics, Inc. Stock

Based on 7 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 7 analysts, 100% of analysts recommend a 'BUY' rating for Maze Therapeutics, Inc.. Average target price of $68.1428571428571

Indian Investors' Interest in Maze Therapeutics, Inc. Stock

Search interest for Maze Therapeutics, Inc. Stock has increased by 200% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:200% versus previous 30 day period

Maze Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
165
2
-
-
-
-
20
-
Gross Profit
-
165
2
-
0
-
0
19
-
Operating Income
-23
139
-24
-35
-36
-32
-38
-26
-48
EBITDA
-25
141
-24
-32
-33
-29
-34
-22
-43
Interest Expense
-
-
-
-
-
-
-
0
0
Depreciation
0
0
0
0
0
0
0
0
-
Income Before Tax
-26
140
-25
-32
-33
-30
-34
-24
-44
Income Tax Expense
-
1
0
-
-
-
-
-
-
Net Income
-26
139
-24
-32
-33
-30
-34
-24
-44
Net Profit Margin
0.00%
100.00%
100.00%
0.00%
0.00%
0.00%
0.00%
97.78%
0.00%

Maze Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Mar 2025
Dec 2025
Total Revenue
-
-
167
-
Gross Profit
-
-
167
-2
Operating Income
-111
-98
57
-142
EBITDA
-111
-96
56
-128
Interest Expense
-
-
-
-
Depreciation
3
4
3
2
Income Before Tax
-114
-100
53
-131
Income Tax Expense
-
-
1
-
Net Income
-114
-100
52
-131
Net Profit Margin
0.00%
0.00%
100.00%
0.00%

Maze Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-26
139
-24
-32
-33
-30
-34
-24
-44
Operating Cash Flow
-20
145
-23
-29
-30
-24
-27
-39
-15
Investing Cash Flow
0
0
0
0
0
-66
-103
6
-128
Financing Cash Flow
16
0
-2
127
0
143
3
42
147
Change in Cash
-4
145
-25
97
-29
52
-127
9
3

Maze Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2022
Dec 2023
Mar 2025
Dec 2025
Net Income
-114
-100
52
-131
Operating Cash Flow
-99
-86
75
-111
Investing Cash Flow
-3
0
-1
-170
Financing Cash Flow
1
16
92
275
Change in Cash
-100
-70
167
-7

Mutual Funds that own Maze Therapeutics, Inc. Stock

Check out the Mutual Funds with significant holdings in Maze Therapeutics, Inc..

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
2.51516%
1397151
Fidelity Select Portfolios
0.561457%
311885
Fidelity Salem Street Trust
0.534099%
296688
Fidelity Concord Street Trust
0.408171%
226736
BlackRock Funds
0.332053%
184453
See all

Global Institutional Holdings in Maze Therapeutics, Inc.

Funds
Holdings
Vanguard
3.69%
iShares
3.39%
Andrew J.M. Spokes
1.99%
Richard Driehaus
1.72%
Michael Rockefeller
1.33%
See all

Insights on Maze Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 478.8% return, outperforming this stock by 475.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, MAZE stock has moved down by -52.7%

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
OrganisationMaze Therapeutics, Inc.
Headquarters171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
IndustryBiotechnology
CEODr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
E-voting on sharesClick here to vote

Key Management of Maze Therapeutics, Inc.

Name

Title

Mr. Misbah Tahir CPA

CFO & Principal Accounting Officer

Dr. Harold S. Bernstein M.D., Ph.D.

President of Research & Development and Chief Medical Officer

Mr. Vipin Vijayakumar

Vice President of R&D Infrastructure and Operations

Ms. Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Ms. Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

Mr. Winston Tse

Senior Vice President of Drug Discovery

Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.

CEO & Director

Mr. Matt Krause

Senior Vice President of Human Resources

Mr. Atul Dandekar

Chief Strategy & Business Officer

Mr. Maarten Hoek

Senior Vice President of Research

FAQs

What is Maze Therapeutics, Inc. share price today?

Maze Therapeutics, Inc. share price today is $24.23 as on at the close of the market. Maze Therapeutics, Inc. share today touched a day high of $24.79 and a low of $24.15.

What is the 52 week high and 52 week low for Maze Therapeutics, Inc. share?

Maze Therapeutics, Inc. share touched a 52 week high of $53.65 on and a 52 week low of $22.04 on . Maze Therapeutics, Inc. stock price today i.e. is closed at $24.23,which is 54.84% down from its 52 week high and 9.94% up from its 52 week low.

What is Maze Therapeutics, Inc.'s market capitalisation today?

Maze Therapeutics, Inc. market capitalisation is $0.00T as on .

How to invest in Maze Therapeutics, Inc. Stock (MAZE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Maze Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Maze Therapeutics, Inc. Shares that will get you 0.0619 shares as per Maze Therapeutics, Inc. share price of $24.23 per share as on September 16, 2026 at 8:46 am IST.

What is the minimum amount required to buy Maze Therapeutics, Inc. Stock (MAZE) from India?

Indian investors can start investing in Maze Therapeutics, Inc. (MAZE) shares with as little as ₹95.94 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹959.40 in Maze Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Maze Therapeutics, Inc. share’s latest price of $24.23 as on September 16, 2026 at 8:46 am IST, you will get 0.4127 shares of Maze Therapeutics, Inc.. Learn more about fractional shares .